𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P162 Treatment of chronic lymphocytic leukaemia in elderly patients with per os fludarabine or fludarabine plus cyclophosphamide

✍ Scribed by Gy. Varga; Z. Borbényi; K. Piukovics

Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
46 KB
Volume
21
Category
Article
ISSN
0268-960X

No coin nor oath required. For personal study only.

✦ Synopsis

lymphocytic leukemia. Besides establishing the demographic characteristics of 322 CLL cases studied, CD38 and ZAP7o was investigated in 58 vs. 64% of the cases while in 57% of the CLL cases FISH analysis for +12,13q ,11q and 17p was possible. Results: (1) The frequency of FISH detected aberrations in 183 CLL patients showed up 20.6; 59.5;11.4 and 8.4% for +12, 13q , 11q and 17p respectively which seems to be in good concordance with literature data. (2) The occurence of ZAP 70 level >20% was more frequent in those CLL cases requiring early therapeutic interventions (1 2 years after the diagnosis).

(3) None of the FISH markers were associated with the time elapsing between the diagnosis and the start of the therapy for CLL. (4) CLL cases with long survival (> 10 years from diagnosis) have revealed an underrepresentation of 11q .

Conclusion:

Prospective studies will answer to what extent these biological parameters will have a role in the risk adopted therapy for CLL.

P160 Alemtuzumab-induced apoptosis in vitro in chronic lymphocytic leukemia with p53 deletion

📜 SIMILAR VOLUMES

Low-dose oral fludarabine plus cyclophos
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia
✍ Francesco Forconi; Alberto Fabbri; Mariapia Lenoci; Elisa Sozzi; Alessandro Gozz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract Fludarabine plus cyclophosphamide (FC) at conventional doses is an effective treatment for chronic lymphocytic leukaemia (CLL). However, FC at standard doses may give hematological and non‐hematological toxicity, predominantly in the elderly. Intravenous or oral low‐dose FC regimens rem

Fractionated cyclophosphamide, vincristi
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage–colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
✍ Apostolia M. Tsimberidou; Hagop M. Kantarjian; Jorge Cortes; Deborah A. Thomas; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Therapy for patients with Richter syndrome (RS) or fludarabine‐refractory chronic lymphocytic leukemia (CLL) is unsatisfactory. A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte‐macrophage–colony s

Combination therapy with fludarabine and
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO